Financial News

Goldman Sachs Neutral On Alder Biopharma As Launch Of Migraine Treatment Approaches

By: via Benzinga
Before Tuesday, 90 percent of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) analysts were buying the stock. But one analyst has diluted ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback